Overview

• CNS biopharmaceutical firm reported wider Q4 net loss of $88.9 mln, with increased R&D expenses

• Praxis submitted NDAs for ulixacaltamide and relutrigine to the FDA

• Company raised $621 mln in January 2026 public offering, funding operations into 2028

Outlook

• Praxis expects topline results for vormatrigine in Q2 2026

• Company anticipates NDA submissions for vormatrigine and elsunersen by 2028

• Praxis expects cash runway to fund operations into 2028

Result Drivers

• NDA SUBMISSIONS - Praxis submitted NDAs for ulixacaltamide and relutrigine, positioning for commercial transition

• COMMERCIAL PREPARATIONS - Co is preparing for the commercial launch of ulixacaltamide and relutrigine, including scaling its commercial organization

• INCREASED R&D EXPENSES - Higher R&D costs driven by investments in Cerebrum and Solidus platforms

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Praxis Precision Medicines Inc is $505.00, about 53.5% above its February 18 closing price of $328.93

Press Release: ID:nGNX1CpNyj

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.